CLDX ▲ +18.8% - Celldex Therapeutics, Inc. $CLDX - Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints Celldex Therapeutics surged 18.8% after announcing that barzolvolimab met its primary endpoint and all key secondary endpoints in both Phase 3 EMBARQ-CSU trials. The positive results advance the company's clinical program for the drug and suggest a potentially successful path toward regulatory approval. 22-SEP-2026 06:58 AM ET